News | February 04, 2025
Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
Morepen Laboratories approves hiving off of medical devices business
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The company has reported total income of Rs. 1,465.49 crores during the period ended September 30, 2024
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The inspection was concluded with two 483 observations
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The product is used to treat amyotrophic lateral sclerosis
Subscribe To Our Newsletter & Stay Updated
